Search clinical trials for: Camrelizumab; apatinib

Total 541 results

Beijing 302 Hospital

Not yet recruiting

Adebrelimab Plus Apatinib and Etoposide for the Treatment of HER2-Negative Breast Cancer Brain Metastasis

HER2-negative Breast Cancer Brain Metastases

China
The First Affiliated Hospital of Xiamen University

Not yet recruiting

A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma

Gastric/Gastroesophageal Junction Adenocarcinoma
The First Affiliated Hospital with Nanjing Medical...

Not yet recruiting

RC48 Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer

Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
Fujian Medical University

Recruiting

A Study of TAE+HAIC Combined With Camrelizumab and Apatinib in the Treatment of Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma

China
Peking University Cancer Hospital & Institute

Recruiting

Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC

Unresectable Hepatocellular Carcinoma

China
LaNova Medicines Zhejiang Co., Ltd.

Not yet recruiting

LM-302 for the Treatment of Subjects With Claudin18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma.

Locally Advanced or Metastatic GC and GCJ Adenocarcinoma
Yongyi Zeng

Not yet recruiting

Neoadjuvant IMRT Combined With Camrelizumab and Apatinib for Resectable HCC With PVTT

Hepatocellular Carcinoma
AstraZeneca

Recruiting

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

Gastric Cancer | Gastroesophageal Junction Cancer

Canada, Spain, United Kingdom, China, France, Italy, Vietnam, Germany, United States, India, Taiwan, Thailand, Hong Kong, Japan, Switzerland, Poland
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma

Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma

China
Chinese PLA General Hospital

Not yet recruiting

A Clinical Study of Adebrelimab Combined With Apatinib and Paclitaxel in Patients With Advanced Gastric Cancer.

Gastric Cancer
Li Huiping

Not yet recruiting

A Multicenter Clinical Study of Apatinib Mesylate Combined With Doctor's Choice for Advanced Breast Cancer

Advanced Breast Cancer
M.D. Anderson Cancer Center
Elevar Therapeutics

Not yet recruiting

A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory Neuroblastoma

Metastatic Olfactory Neuroblastoma | Recurrent Olfactory Neuroblastoma

United States
Lei ZHAO

Recruiting

Perioperative Treatment of Resectable Intrahepatic Cholangiocarcinoma With the Combination of Adebrelimab and Apatinib and HAIC

Intrahepatic Cholangiocarcinoma

China
Sun Yat-sen University

Recruiting

Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell Carcinoma

Efficacy | Toxicity | Esophageal Squamous Cell Carcinoma

China
Meng Chao Hepatobiliary Hospital of Fujian Medical...

Not yet recruiting

A Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Failed Camrelizumab Combined With Apatinib

Hepatocellular Carcinoma

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Chemotherapy Combined With Adebrelimab and Apatinib as the Perioperative Treatment in Patients With Biliary Tract Cancer

Resectable Intrahepatic Cholangiocarcinoma With High Risk of Recurrence

China
Amneal Pharmaceuticals, LLC
CBCC Global Inc.; Amneal EU, Limited

Not yet recruiting

A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes

Ocular Hypertension | Open-angle Glaucoma

United States
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not yet recruiting

Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer

Breast Cancer

China
Samsung Medical Center

Not yet recruiting

Rivoceranib in Patients With Metastatic Thymic Epithelial Tumor

Thymic Epithelial Tumor

Korea, Republic of
The First Affiliated Hospital of Xiamen University

Not yet recruiting

Maintenance Therapy After Platinum-containing Chemotherapy in Patients With Recurrent Ovarian Cancer

Ovarian Cancer
First Affiliated Hospital of Fujian Medical University

Recruiting

A Study of Adebrelimab in Combination With Apatinib Gemcitabine and Cisplatin in Biliary Tract Malignancies

Biliary Tract Malignancies

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC

Chemotherapy Effect | BCLC Stage C Hepatocellular Carcinoma

China
Guangxi Medical University

Not yet recruiting

Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma | High Grade Serous Adenocarcinoma of Ovary

China
Peking Union Medical College
Peking University Hospital of Stomatology

Recruiting

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

Precision Therapy | Locally Advanced or Recurrent/Metastatic Salivary Gland Carcinoma | Neoadjuvant or Conversion Therapy

China
Xuanwu Hospital, Beijing

Recruiting

Apatinib Combined With Camrelizumab in Treating Participants With Advanced Chordoma

Chordoma | Chemotherapy Effect

China
Wuhan Union Hospital, China

Not yet recruiting

Tucidinostat Plus Apatinib for Advanced Osteosarcoma

Osteosarcoma
Qilu Hospital of Shandong University

Not yet recruiting

The Efficacy and Safety of Fluzopril Combined With Apatinib in Maintenance Treatment of Platinum Resistant Recurrent Ovarian Cancer Patients

Ovarian Cancer Recurrent
Peking University Cancer Hospital & Institute

Recruiting

KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 Blockade

Digestive System Cancers

China
Jin Li

Not yet recruiting

Fluzoparib Combined With Apatinib in Relapsed Ovarian Carcinoma Maintenance Treatment

Relapsed Ovarian Cancer
Tanta University

Recruiting

Role of Vitamin K2 in Chronic Kidney Disease

Chronic Kidney Diseases

Egypt
Tianjin Medical University Cancer Institute and...

Recruiting

Continuation of Serplulimab Plus Chemotherapy After First Progression in Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma: an Open-label, Randomised Phase II Trial

Gastric Cancer (GC) Gastroesophageal Junction Cancer (GEJ)

China
Nicox Ophthalmics, Inc.

Recruiting

Aqueous Humor Dynamics of NCX 470 Ophthalmic Solution (Whistler)

Open Angle Glaucoma

United States
Sun Yat-sen University

Not yet recruiting

Apatinib and Fluzoparib With or Without Adebrelimab in Previously-treated TP53-mutant Advanced Non-small Cell Lung Cancer

NSCLC | Non-small Cell Lung Cancer

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Adebrelimab, Camrelizumab Plus Apatinib as First-line Therapy in Patients With Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma

China
Asan Medical Center

Recruiting

Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor

Gastrointestinal Stromal Tumors

Korea, Republic of
Fudan University

Not yet recruiting

A Randomized, Controlled, Open-label Clinical Trial of Adjuvant Intensive Therapy for HR+/ HER2-SNF4 Early Breast Cancer

HR+/HER2-breast Cancer
Sun Yat-sen University

Recruiting

Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC

Nasopharyngeal Carcinoma

China
Tianjin Medical University Cancer Institute and...

Recruiting

Surgical Conversion of Candonilimab (AK104) Plus Paclitaxel, S-1 and Apatinib for Unresectable Advanced G/GEJ Cancer

Gastric Cancer

China
Wan-Guang Zhang

Recruiting

A Single-arm Clinical Study of HAIC Combined With Apatinib and Camrelizumab in the Treatment of Unresectable MTM HCC (CCGLC-010)

Macrotrabecular Massive Hepatocellular Carcinoma

China
Peking University Cancer Hospital & Institute

Recruiting

Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma

Acral Melanoma

China
Fudan University
Chongqing University Cancer Hospital; Sun Yat-sen University; Peking University... and other collaborators

Recruiting

Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer

Breast Cancer Metastatic

China
Xiangya Hospital of Central South University
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST

Gastrointestinal Stromal Tumors

China
Sun Yat-sen University
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Not yet recruiting

A Phase Ib/II Clinical Study of Camrelizumab and Apatinib Plus GP in the Treatment of Advanced Biliary Tract Cancer

Metastatic Biliary Tract Cancer | Locally Advanced Biliary Tract Cancer

China
The First Affiliated Hospital of Zhengzhou University

Recruiting

Camrelizumab in Combination With Apatinib Mesylate Plus Short-course Chemotherapy for Advanced ESCC

Esophageal Cancer by AJCC V8 Stage

China
Tongji Hospital
The Second Affiliated Hospital of Fujian Medical University; Geneplus-Beijing... and other collaborators

Recruiting

Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma (CCGLC-008)

Hepatocellular Carcinoma Non-resectable

China
Wan-Guang Zhang
The Second Affiliated Hospital of Fujian Medical University; Geneplus-Beijing... and other collaborators

Recruiting

Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma (CCGLC-001)

Hepatocellular Carcinoma Non-resectable

China
Fujian Cancer Hospital

Recruiting

Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer

Immunotherapy Gastrict Cancer

China
Fudan University
Huazhong University of Science and Technology; LinkDoc Technology (Beijing)...

Not yet recruiting

Effect and Safety of Huaier Granules Combined With Targeted Drugs and Anti-PD-(L)1 Antibody Compared With Targeted Drugs Combined With Anti-PD-(L)1 Antibody in First Line Treatment of Unresectable Hepatocellular Carcinoma(uHCC)

Unresectable Hepatocellular Carcinoma
First Affiliated Hospital Xi'an Jiaotong University

Not yet recruiting

Advanced or Metastatic Cholangiocarcinoma

Cholangiocarcinoma
National Institute of Allergy and Infectious Diseases...
ViiV Healthcare; Mylan Inc.

Recruiting

Pharmacokinetics and Safety of Double-dose Dolutegravir When Used With Rifapentine for HIV-associated Tuberculosis

HIV-associated Tuberculosis

South Africa, Thailand

3

Subscribe